Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2022

Summary of Total Consolidated Revenue from Strategic Collaborators

The following table summarizes our total consolidated revenue from our current and former strategic collaborators for the periods presented (in thousands):

	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
Collaboration Revenue by Strategic Collaborator:	2022			2021			2022			2021
Jazz	$	13,312		$	(511	)	$	26,016		$	11,107
Sarepta		(167	)		1,401			(167	)		2,974
Total collaboration revenue	$	13,145		$	890		$	25,849		$	14,081

Schedule of Changes in Contract Assets and Liabilities

The following tables present changes in the Company’s contract assets and liabilities for the period presented (in thousands):

	SIX MONTHS ENDED JUNE 30, 2022
	BALANCE BEGINNING OF PERIOD		ADDITIONS		DEDUCTIONS			BALANCE END OF PERIOD
Contract assets:
Account receivable (1)	$	628		—		(628	)	$	—
Contract liabilities:
Deferred revenue	$	43,649		—		(26,016	)	$	17,633

(1)Included in prepaid expenses and other current assets as shown within the condensed consolidated balance sheets.

Schedule of Revenue Recognized

During the three and six months ended June 30, 2022 and 2021, the Company recognized the following revenue (in thousands):

	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2022		2021		2022		2021
Revenue recognized in the period from:
Amounts included in deferred revenue at the beginning of the period	$	13,312	$	890	$	26,016	$	14,081

Jazz Pharmaceuticals Ireland Limited

Schedule of Research and Development Costs Incurred and Revenue Recognized

The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Jazz Collaboration Agreement (in thousands):

	THREE MONTHS ENDED JUNE 30,					SIX MONTHS ENDED JUNE 30,
	2022		2021			2022		2021
Revenue recognized	$	13,312	$	(511	)	$	26,016	$	11,107
Costs incurred	$	393	$	677		$	952	$	1,341

Sarepta Therapeutics

Schedule of Research and Development Costs Incurred and Revenue Recognized

The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Sarepta Research Agreement (in thousands):

	THREE MONTHS ENDED JUNE 30,					SIX MONTHS ENDED JUNE 30,
	2022			2021		2022			2021
Revenue recognized	$	(167	)	$	1,401	$	(167	)	$	2,974
Costs incurred	$	—		$	1,401	$	—		$	2,974